Ellen Chiniara Sells 3,129 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Ellen Chiniara sold 3,129 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Kymera Therapeutics Price Performance

KYMR stock opened at $40.92 on Wednesday. Kymera Therapeutics, Inc. has a one year low of $25.02 and a one year high of $53.27. The stock has a market cap of $2.65 billion, a price-to-earnings ratio of -17.49 and a beta of 2.19. The company has a fifty day moving average price of $44.34 and a two-hundred day moving average price of $43.94.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics’s revenue was down 20.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.90) EPS. Research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Large investors have recently made changes to their positions in the company. Massachusetts Financial Services Co. MA increased its position in Kymera Therapeutics by 11.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock worth $21,458,000 after buying an additional 47,507 shares during the period. Bank of New York Mellon Corp raised its stake in Kymera Therapeutics by 19.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company’s stock worth $4,663,000 after purchasing an additional 25,317 shares in the last quarter. Eventide Asset Management LLC boosted its holdings in Kymera Therapeutics by 9.9% in the 3rd quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock valued at $24,039,000 after purchasing an additional 45,803 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Kymera Therapeutics during the 2nd quarter worth approximately $4,271,000. Finally, E Fund Management Co. Ltd. increased its holdings in shares of Kymera Therapeutics by 391.2% during the second quarter. E Fund Management Co. Ltd. now owns 48,946 shares of the company’s stock worth $1,461,000 after purchasing an additional 38,981 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on KYMR. Morgan Stanley upped their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 6th. UBS Group decreased their price target on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. BMO Capital Markets assumed coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective on the stock. Leerink Partners reaffirmed an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. Finally, Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $55.38.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.